Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2012 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (431)	1/1/2013 10:32:51 PM
From: mcbio	Read Replies (1) \| Respond to of 513

They also have talked about how there is chance for better efficacy in 2nd P3 trial given that many more patients in this trial are overseas and these patients tend to have much bigger lesions and tedizolid performed much better vs. Zyvox in patients w/larger lesions. Who knows if this is how it will play out though, of course. The other thing for me is that they intend to keep U.S. rights and likely may not need huge sales, given that, to move the dial from current valuation. Always appreciate your view too, of course. I could be way off here.